RE:RE:News!This logic is so flawed and rosy (fully expected from the Barron). June isn't going to prop the price like Witkowski's first presentation. The fact it works is baked into the price already, we all know it does. Everyone now is expecting that the other 3 patients are going to have the same results. If they do, business as usual. If they don't though, then we have big problem. These patients need to completely off insulin and without an extra portal vein injection. Short of that, the stock will likely fall. The first presentation showed investors that the technology at least works on one patient and the investment was de-risked. You won't see that same reaction with the next presentation. We have more chances of it to go down than up if any of the other patients dont' have better results than the first. These are brittle diabetics and are prone to all kinds of health problems. Heaven forbid one of them catch covid or run into other health complications. Nothing is a sure bet, get your investment and profit out and let the free stuff ride. Definately some upside potential here, don't get me wrong, but not without major risks.
Redbaron2211 wrote: Bio if you looked at Witkowski's site you would have seen that this was pending approval of organizers. Now confirmed this is another significant milestone to look forward to. Given what happened last time witkowski presented data it has potential of being a major catalyst.